These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 1975737)

  • 1. Comparison of the single dose pharmacokinetics of sulphasalazine in rheumatoid arthritis and inflammatory bowel disease.
    Astbury C; Taggart AJ; Juby L; Zebouni L; Bird HA
    Ann Rheum Dis; 1990 Aug; 49(8):587-90. PubMed ID: 1975737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma and synovial fluid concentrations of sulphasalazine and two of its metabolites in rheumatoid arthritis.
    Farr M; Brodrick A; Bacon PA
    Rheumatol Int; 1985; 5(6):247-51. PubMed ID: 2906452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.
    Day JM; Houston JB
    Br J Clin Pharmacol; 1980 Jan; 9(1):91-4. PubMed ID: 6101957
    [No Abstract]   [Full Text] [Related]  

  • 4. Further studies of sulphasalazine metabolism in the treatment of ulcerative colitis.
    Cowan GO; Das KM; Eastwood MA
    Br Med J; 1977 Oct; 2(6094):1057-9. PubMed ID: 21720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of interaction between sulphasalazine and cimetidine in patients with rheumatoid arthritis.
    Pirmohamed M; Coleman MD; Galvani D; Bucknall RC; Breckenridge AM; Park BK
    Br J Rheumatol; 1993 Mar; 32(3):222-6. PubMed ID: 8095423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis?
    Taggart AJ; Neumann VC; Hill J; Astbury C; Le Gallez P; Dixon JS
    Drugs; 1986; 32 Suppl 1():27-34. PubMed ID: 2877851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which component of sulphasalazine is active in rheumatoid arthritis?
    Pullar T; Hunter JA; Capell HA
    Br Med J (Clin Res Ed); 1985 May; 290(6481):1535-8. PubMed ID: 2860942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation.
    Esbjörner E; Järnerot G; Wranne L
    Acta Paediatr Scand; 1987 Jan; 76(1):137-42. PubMed ID: 2882643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disposition of metronidazole and its effects on sulphasalazine metabolism in patients with inflammatory bowel disease.
    Shaffer JL; Kershaw A; Houston JB
    Br J Clin Pharmacol; 1986 Apr; 21(4):431-5. PubMed ID: 2871853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulphasalazine in the treatment of rheumatoid arthritis: relationship of dose and serum levels to efficacy.
    Pullar T; Hunter JA; Capell HA
    Br J Rheumatol; 1985 Aug; 24(3):269-76. PubMed ID: 2861876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Determination of sulfapyridine levels in serum--a possibility for the control of dose related therapy with sulfasalazine].
    Eitner K; Reinicke C; Hippius M
    Dtsch Z Verdau Stoffwechselkr; 1984; 44(6):282-8. PubMed ID: 6151895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative pharmacokinetics of sulphasalazine and sulphapyridine after rectal and oral administration to patients with ulcerative colitis.
    Allgayer H; Kruis W; Eisenburg J; Paumgartner G
    Eur J Clin Pharmacol; 1984; 26(2):275-7. PubMed ID: 6144549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of sulphasalazine.
    Das KM; Dubin R
    Clin Pharmacokinet; 1976; 1(6):406-25. PubMed ID: 15752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The pharmacokinetics of sulphasalazine in young and elderly patients with rheumatoid arthritis.
    Taggart AJ; McDermott B; Delargy M; Elborn S; Forbes J; Roberts SD; Ahnfelt NO
    Scand J Rheumatol Suppl; 1987; 64():29-36. PubMed ID: 2893450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.
    Klotz U
    Clin Pharmacokinet; 1985; 10(4):285-302. PubMed ID: 2864155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulphasalazine-induced leucopenia in a patient with renal dysfunction.
    Teshima D; Hino B; Makino K; Yano T; Itoh Y; Joh Y; Iida M; Oishi R
    J Clin Pharm Ther; 2003 Jun; 28(3):239-42. PubMed ID: 12795783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulphasalazine treatment during breast feeding.
    Järnerot G; Into-Malmberg MB
    Scand J Gastroenterol; 1979; 14(7):869-71. PubMed ID: 44005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating levels of sulphasalazine and its metabolites and their relation to the clinical efficacy of the drug in ulcerative colitis.
    Azad Khan AK; Truelove SC
    Gut; 1980 Aug; 21(8):706-10. PubMed ID: 6107264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease.
    Laasila K; Leirisalo-Repo M
    Scand J Rheumatol; 1994; 23(6):338-40. PubMed ID: 7801059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of rifampicin on sulphapyridine plasma concentrations following sulphasalazine administration.
    Shaffer JL; Houston JB
    Br J Clin Pharmacol; 1985 Apr; 19(4):526-8. PubMed ID: 2859874
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.